Novel antipsychotics in the long-term treatment of schizophrenia

World Journal of Biological Psychiatry

Volumn 5, Issue 1, 2004, Pages 9-19

  Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Depot neuroleptics; Long term treatment of schizophrenia; Oral long term treatment; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIPARASITIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; PLACEBO; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; MOTOR DYSFUNCTION; PATIENT COMPLIANCE; PSYCHOEDUCATION; RECURRENCE RISK; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN; CLASSIFICATION; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; HEALTH PROMOTION; RECURRENT DISEASE;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HEALTH PROMOTION; HUMANS; PATIENT COMPLIANCE; RECURRENCE; SCHIZOPHRENIA;

EID: 4644364741     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970410029902     Document Type: Review

References (48)

1. Arato, M and O'Connor, R and Meltzer, H and Zeus study group. (2002) Ziprasidone in the long-term treatment of negative symptoms and the prevention of exacerbation of schizophrenia Int Clin Psychopharmacol, 17, pp. 17-207.
2. Bäuml, J and Kissling, W and Meurer, C and Wais, A and Lauter, H. (1991) Informationszentrierte Angehörigengruppe zur Complianceverbesserung bei schizophrenen Patienten Psychiatr Prax, 18, pp. 18-48.
3. Beasley, C and Hamilton, S and Dossenbach, M. (2000) Relapse prevention with olanzapine Eur Neuropsychopharmacol, 10, pp. S304.
4. Buchkremer, G and Schulze-Mönking, H and Holle, R and Hornung, W. (1995) The impact of therapeutic relatives' groups on the course of illness of schizophrenic patients Eur Psychiat, 10, pp. 10-17.
5. Cheung, H. (1981) Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs Br J Psychiat, 138, pp. 138-490.
6. Chue, P and Eerdekens, M and Augustyns, I and Lachaux, B and Molcan, P and Eriksson, L and Pretorius, H and David, A. (2002) Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets Schizophr Bull, 53, pp. 53-174.
7. Cooper, S and Butler, A and Tweed, J and Welch, C and Raniwalla, J. (2000) Zotepine in the prevention of recurrence: A randomised, double-blind, placebo-controlled study for chronic schizophrenia Psychopharmacology (Berl), 150, pp. 150-237.
8. Cramer, J and Rosenheck, R. (1998) Compliance with medication regimens for mental and physical disorders Psychiatr Serv, 49, pp. 49-196.
9. Csernansky, J and Mahmoud, R and Brenner, R. (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia N Engl J Med, 346, pp. 346-16.
10. Daniel, D and Wozniak, P and Mack, R and McCarthy, B. (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia Psychopharmacol Bull, 34, pp. 34-61. The Sertindole Study Group
11. Davis, J and Matalon, L and Watanabe, M and Blake, L and Metalon, L. (1994) Depot antipsychotic drugs Place in therapy. Drugs, 47, pp. 47-741.
12. Dellva, M and Tran, P and Tollefson, G and Wentley, A and Beasley, C-MJ. (1997) Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia Psychiatr Serv, 48, pp. 48-1571.
13. Eerdekens, M and Fleischhacker, W and Xie, Y and Gefvert, O. (2002) Long-term safety of long-acting risperidone microspheres Schizophr Bull, 53, pp. 174.
14. Essock, S and Hargreaves, W and Covell, N and Goethe, J. (1996) Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial Psychopharmacol Bull, 32, pp. 32-683.
15. Fenton, W and Blyler, C and Heinssen, R. (1997) Determinants of medication compliance in schizophrenia: Empirical and clinical findings Schizophr Bull, 23, pp. 23-637.
16. Gaebel, W. (1995) Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment? Int Clin Psychopharmacol, 9(Suppl 5), pp. 11-16.
17. Hirsch, S and Gaind, R and Rohde, P and Stevens, B and Wing, J. (1973). Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. In Br Med [pp. 17-633].
18. Hogarty, G and Goldberg, S. (1973) Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates Arch Gen Psychiatry, 28, pp. 28-54.
19. Hogarty, G and Goldberg, S and Schooler, N and Ulrich, R. (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-years relapse rates Arch Gen Psychiatry, 31, pp. 31-603.
20. Jolley, A and Hirsch, S and Morrison, E and McRink, A and Wilson, L. (1990) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two years BMJ, 301, pp. 301-837.
21. Kane, J and Aguglia, E and Altamura, A and Ayuso-Gutierrez, J and Brunello, N and Fleischhacker, W and Gaebel, W and Gerlach, J and Guelfi, J and Kissling, W and et, al. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. In Eur Neuropsychopharmacol [pp. 8-55].
22. Kane, J and Eerdekens, M and Lindenmayer, J and Keith, S and Lesem, M and Karcher, K. (2003) Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic Am J Psychiatry, 160, pp. 160-1125.
23. Leff, J and Wing, J. (1971) Trials of maintenance therapy in schizophrenia Br Med J, III, pp. 599-604.
24. Leucht, S and Barnes, T and Kissling, W and Engel, R and Correll, C and Kane, J. (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized controlled trials Am J Psychiatry, 160, pp. 160-1209.
25. Lieberman, J and Koreen, A and Chakos, M and Sheitman, B and Woerner, M and Alvir, J and Bilder, R. (1996) Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia J Clin Psychiatry, 9(Suppl), pp. 9-5.
26. Loo, H and Poirier-Littre, M and Theron, M and Rein, W and Fleurot, O. (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia Br J Psychiat, 170, pp. 170-18.
27. Marder, S and Van Putten, T and Mintz, J and Lebell, M and McKenzie, J and May, P. (1987) Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome Arch Gen Psychiatry, 44, pp. 44-518.
28. Marder, S and Glynn, S and Wirshing, W and Wirshing, D and Ross, D and Widmark, C and Mintz, J and Lieberman, J and Blair, K. (2003) Maintenance treatment of schizophrenia with risperidone or haloperidol: two-year outcomes Am J Psychiatry, 160, pp. 160-1405.
29. Meltzer, H and Alphs, L and Green, A and Altamura, A and Anand, R and Bertoli, A and Bourgeois, M and Chouinard, G and Islam, M and Kane, J et al. (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial(InterSePT) Arch Gen Psychiatry, 60, pp. 82-91.
30. Möller, H. (1990) Neuroleptische Langzeittherapie schizophrener Erkrankungen. In Leitlinien neuroleptischer Therapie. (pp. 97-115). Berlin Heidelberg: Springer.
31. Möller, H. (2000a) State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics World J Biol Psychiatry, 1, pp. 204-214.
32. Möller, H. (2000b) Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: Methodological issues and clinical consequences World J Biol Psychiatry, 1, pp. 75-91.
33. Möller, H. (In Press a) Antipsychotic agents - gradually improving treatment Br J Psychiat.
34. Möller, H. (In Press b) Depressive Comorbidität/ Co-syndromi-bidität im Rahmen schizophrener Psychosen und ihre Therapie. In Schizophrene Störungen -State of the art. Innsbruck: VIP-Verlag.
35. Möller, H and von Zerssen, D. (1986) Der Verlauf schizophrener Psychosen unter den gegenwärtigen Behandlungsbedingungen. In. Berlin Heidelberg: Springer.
36. Möller, H and Kissling, W and Stoll, K and Wendt, G. (1989) Psychopharma-kotherapie. In Ein Leitfaden für Klinik und Praxis. Stuttgart: Kohlhammer.
37. Möller, H and Gagiano, C and Addington, D and Von Knorring, L and Torres-Plank, J-F and Gaussares, C. (1998) Long-term treatment of chronic schizophrenia with risperidone: An open-label, multicenter study of 386 patients. In (pp. 99-106). Int Clin Psychopharmacol
38. Möller, H and Bottlender, R and Groß, A and Hoff, P and Wittmann, J and Wegner, U and Strauss, A. (2002) The Kraepelinian dichotomy: Preliminary results of a 15-year follow-up study on functional psychoses: Focus on negative symptoms Schizophr Res, 56, pp. 87-94.
39. Müller, P. (1982) Die patienten und das Ergebnis der Rezidivprophylaxe. In zur Rezidivprophylaxe schizophrener Psychosen. (pp. 15-23). Stuttgart: Enke.
40. Oehl, M and Hummer, M and Fleischhacker, W. (2000) Compliance with antipsychotic treatment Acta Psychiatr Scand Suppl, 102, pp. 83-86.
41. Rabinowitz, J and Lichtenberg, P and Kaplan, Z and Mark, M and Nahon, D and Davidson, M. (2001) Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics Am J Psychiatry, 158, pp. 266-269.
42. Rifkin, A and Quitkin, F and Rabiner, C and Klein, D. (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year Arch Gen Psychiatry, 34, pp. 43-47.
43. Rosenheck, R and Evans, D and Herz, L and Cramer, J and Xu, W and Thomas, J and Henderson, W and Charney, D. (1999) How long to wait for a response to clozapine: A comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia Schizophr Bull, 25, pp. 709-719.
44. Rosenbeck, R and Chang, S and Choe, Y and Cramer, J and Weichun, X and Thomas, J and Henderson, W and Charney, D. (2000) Medication continuation and compliance: A comparison of patients treated with clozapine and haloperidol J Clin Psychiatry, 61, pp. 382-386.
45. Speller, J and Barnes, T and Curson, D and Pantelis, C and Alberts, J. (1997) One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol Br J Psychiatry, 171, pp. 564-568.
46. Tamminga, C and Thaker, G and Moran, M and Kakigi, T and Gao, X. (1994) Clozapine in tardive dyskinesia: Observations from human and animal model studies J Clin Psychiatry, 55(Suppl B), pp. 102-106.
47. Tran, P and Dellva, M and Tollefson, G and Wentley, A and Beasley, C-MJ. (1998) Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses Br J Psychiatry, 172, pp. 499-505.
48. Volz, H and Kasper, S and Möller, H and Sachs, G and Höse, A. (2003) Die Rolle der Kognition in der Therapie schizophrener Störungen. In. Wiesbaden: Deutscher Universitäts-Verlag.